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Recent work has identified a new subset of ef-
fector T cells that produces interleukin (IL)-17
known as T helper 17 (Th17) cells, which is in-
volved in the pathophysiology of inflammatory
diseases and is thought to be developmentally
related to regulatory T (Treg) cells. Because of
its importance for Treg cells, we examined the
role of IL-2 in Th17 generation and demonstrate
that a previously unrecognized aspect of IL-2
function is to constrain IL-17 production.
Genetic deletion or antibody blockade of IL-2
promoted differentiation of the Th17 cell sub-
set. Whereas STAT3 appeared to be a key pos-
itive regulator of RORgt and IL-17 expression,
absence of IL-2 or disruption of its signaling
by deletion of the transcription factor STAT5 re-
sulted in enhanced Th17 cell development. We
conclude that in addition to the promotion of
activation-induced cell death of lymphocytes
and the generation of Treg cells, inhibition of
Th17 polarization appears to be an important
function of IL-2.
INTRODUCTION
In response to various infectious organisms, the adaptive
immune system generates distinct responses, which in
part are governed by the pattern of cytokines secreted
by effector T cells. Although T helper (Th) cells secrete
an array of cytokines, until recently, these cells were di-
vided into two groups on the basis of their cytokine pro-
files: Th1 cells that secrete IFN-g and Th2 cells that
secrete IL-4, IL-5, and IL-13 (Abbas et al., 1996; Flavell,
1999; Glimcher, 2001; Mosmann and Coffman, 1989;
Murphy and Reiner, 2002). Th1 cells are essential for con-trolling intracellular infectious organisms whereas Th2
cells are important for host defense against helminth in-
fections. These Th cell lineages have also been implicated
in the pathogenesis of immune-mediated disease. For in-
stance, Th1 cells have been thought to contribute to pa-
thology in Crohn’s disease (Strober et al., 1998), whereas
Th2 cells have been implicated in asthma (Umetsu et al.,
2002). In general, though, autoimmune diseases are not
easily explained by a dichotomous view of helper T cell
differentiation.
The interleukin (IL)-17 family members 17A and 17F
have been implicated in host defense against extracellular
bacteria; IL-17 receptor-deficient mice are susceptible to
bacterial pneumonias and are unable to form abdominal
abscesses (Ye et al., 2001). Importantly though, IL-17
has also been found to be overexpressed in a variety of
autoimmune and autoinflammatory syndromes, both in
mice and in humans (McKenzie et al., 2006). The identifi-
cation of a helper T cell lineage that selectively produced
IL-17 was therefore of considerable interest (Aggarwal
et al., 2003; Bettelli et al., 2006; Cua et al., 2003; Harring-
ton et al., 2005; Langrish et al., 2005; Mangan et al., 2006;
Murphy et al., 2003; Veldhoen et al., 2006a). Initially, it was
thought that IL-23 induced the formation of Th17 effector
cells; however, it is now thought that IL-23 maintains and
expands this population of cells. The cytokines now
thought to be critical for promoting Th17 differentiation
are transforming growth factor (TGF)-b1 and IL-6 (Bettelli
et al., 2006; Mangan et al., 2006; Veldhoen et al.,
2006a). In conjunction with T cell receptor stimulation,
these cytokines induce the expression of the orphan nu-
clear receptor RORgt, which is critical for Th17 differen-
tiation (Ivanov et al., 2006). These findings are also of inter-
est in that TGF-b1 is important for maintenance peripheral
regulatory T (Treg) cells (Li et al., 2006; Marie et al., 2006).
That is, TGF-b1 alone promotes expression of the tran-
scription factor FoxP3, whereas the combination of IL-6,
TGF-b1 suppresses FoxP3 expression and enhances
IL-17 production. Thus, the differentiation of Treg and
Th17 cells by TGF-b1 appears to be reciprocally related,Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 371
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IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 1. IL-2 Restricts In Vitro Generation of IL-17-Secreting CD4+ T Cells
(A and B) Sorted naive (CD62L+ CD44 CD25) CD4+ T cells from wild-type C57Bl6 mice were stimulated with anti-CD3 and anti-CD28 in media
alone or under optimal Th17-polarizing conditions for 3 days and analyzed by flow cytometry for the presence of intracellular cytokines. Percentages
of CD4+ T cells positive for intracellular IFN-g or IL-17 are shown after culture in the presence of 0, 10, 50, or 100 iu/ml of exogenous rhIL-2. Shown in
(B) are three experiments analyzing both the effect of increasing doses of rhIL-2 as described above and the addition of anti-mouse IL-2 and its rescue
with the addition of rhIL-2 at 100 iu/mL. Significant differences were determined by Student’s t test and are denoted by a double asterisk (p < 0.01) or
by a triple asterisk (p < 0.001).
(C and D) CD4+ T cells were cultured as in (A), but in the absence (top rows) or presence (bottom rows) of a blocking antibody for murine IL-2, without
(middle columns) or with (right columns) exogenous rhIL-2. Intracellular staining for IFN-g versus IL-17 (C) or FoxP3 versus IL-17 (D) is shown.through the action of IL-6 (Bettelli et al., 2006; Veldhoen
et al., 2006a, 2006b).
The development of Treg cells is regulated by IL-2 and
IL-2Ra chain (Shevach et al., 2006). Accordingly, Il2/
and IL2ra/mice develop systemic autoimmune disease
characteristic of reduced Treg cell numbers (Suzuki et al.,
1995; Abbas, 2003; Malek, 2003; Refaeli and Abbas,
1998; Refaeli et al., 1999). In view of the apparent connec-
tion between Treg and Th17 cells (Bettelli et al., 2006), we
were interested in exploring whether IL-2 had a role in
Th17 differentiation. In the present study, we report that
IL-2 negatively regulates Th17 differentiation and appears
to be a mechanism for regulating the balance between
Th17 and Treg cells.372 Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc.RESULTS
IL-2 Inhibits In Vitro Differentiation of Th17 Cells
We first examined the potential role of IL-2 in Th17 gener-
ation by using several complementary approaches. As
previously reported, in vitro culture of naive CD4+ T cells
with IL-6 and TGF-b1 along with blocking antibodies
against IL-4 and interferon (IFN)-g (denoted henceforth
as optimal Th17 conditions) resulted in an increased pro-
portion of cells that selectively produce IL-17 and not
IFN-g compared to cells cultured in medium alone (Fig-
ure 1A). We first assessed a role for IL-2 by adding
excess exogenous IL-2 to these cultures. This resulted
in a dose-dependent decrease in the proportion of
Immunity
IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 2. IL-2 Inhibits IL-17 Production
Both In Vitro and In Vivo
(A) CD4+ T cells fromwild-type or Il2/C57Bl6
mice were stimulated with anti-CD3 and anti-
CD28 under Th17 conditions for 3 days in the
presence or absence of IL-2, followed by intra-
cellular staining for IFN-g versus IL-17. The
numbers indicate the percentage of CD4+ T
cells that express IL-17 and are representative
of data from two independent experiments.
(B) Serum concentrations of IL-17 were ana-
lyzed in Il2/ (n = 5) and wild-type (n = 5) mice
by ELISA. The amounts were significantly
different (p = 0.02) as assessed by an unpaired
(unequal variance) test and are denoted by
a single asterisk (p < 0.05).
(C) Mesenteric lymph node cells fromwild-type
and Il2/ mice were harvested, stimulated for
4 hr with PMA and ionomycin, fixed, and
stained for the presence of IL-17 and the ex-
pression of CD4 by flow cytometry. The num-
bers shown indicate the percentage of total
cells and are representative of data from two
independent experiments.IL-17-producing cells with no change in the proportion of
IFN-g-producing cells (Figure 1A). Activated T cells pro-
duce endogenous IL-2, so we next investigated the contri-
bution of this cytokine by adding IL-2 antibodies. Block-
ade of IL-2 in these cultures increased the proportion of
IL-17-producing cells, as determined by intracellular cyto-
kine staining (Figures 1B–1D) and ELISA (data not shown);
conversely, addition of exogenous human IL-2 reversed
this effect. After 3 days of culture, the addition of human
IL-2 to the sample receiving anti-mouse IL-2 resulted in
a small increase in cell number that was not statistically
significant (0.7 3 106 cells/ml ± 0.22 versus 1.01 3 106
cells/ml ± 0.25, p = 0.11). Additionally, we observed a de-
crease in the percentage of FoxP3-positive cells that was
inversely proportional to the increased percentage of
IL-17-producing cells when IL-2 was blocked (Figure 1D).
Thus, these data illustrate the ability of IL-2 to expand Treg
cells and simultaneously restrict Th17 development. This
is consistent with the idea that Treg and Th17 cells may
be reciprocally regulated (Bettelli et al., 2006); in this
case, IL-2 is an important factor in fate determination of
both lineages. It is notable that TGF-b1, an important fac-
tor for Th17 polarization, is an inhibitor of IL-2 production;
this could be one means by which this cytokine promotes
differentiation of this lineage (McKarns et al., 2004).
IL-2 Deficiency Is Associated with Enhanced
IL-17 Production
To more clearly define a role of IL-2 in Th17 polarization,
we took a third approach of culturing Il2/ CD4+ T cells
in vitro under Th17-polarizing conditions in the presence
or absence of exogenous IL-2. As shown in Figure 2A, T
cells from Il2/ mice had a marked increase in the per-
centage of IL-17-producing cells compared to wild-typecells. Addition of IL-2 into polarizing cultures reduced
the percentage of IL-17-producing cells in wild-type cells
and normalized IL-17 production by Il2/ cells. These
data substantiate the contention that IL-2 limits IL-17 pro-
duction. The addition of IL-2 to Il2/ T cells had no signif-
icant increase in cell number after 3 days of T cell receptor
stimulation (see Figure S1 in the Supplemental Data avail-
able online) irrespective of culture condition.
To determine whether IL-2 was an important in vivo
regulator of IL-17 homeostasis, we next measured serum
concentration of IL-17 in 3-month-old wild-type versus
Il2/ mice. Whereas IL-17 was undetectable in normal
mice, Il2/mice had significantly elevated concentration
of this cytokine in serum (Figure 2B, p = 0.02). The mesen-
teric lymph nodes from Il2/ and wild-type mice were
analyzed for the presence of IL-17-expressing cells: con-
sistent with the elevated concentration of IL-17 in serum,
peripheral lymph nodes from Il2/ lymph node cells had
a greater proportion of IL-17-positive cells, most of which
were CD4 positive (Figure 2C). Taking into account the
peripheral lymphadenopathy associated with Il2/ mice,
there was a 30-fold difference in absolute numbers of
mesenteric Th17 cells compared with wild-type mice
(data not shown).
IL-2 Deficiency Is Associated with Enhanced Th17
Cell Generation In Vivo
Because of the widespread autoimmune disease in Il2/
mice and the activated phenotype of CD4+ T cells from
these animals, we thought it important to confirm the re-
quirement of IL-2 for suppression of Th17 cells by using
a different system. To eliminate the potentially confound-
ing aspect of autoimmune disease, we used mice
deficient in IL-2 that express a restricted T cell receptorImmunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 373
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IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 3. IL-2 Inhibits IL-17 Production in the Absence of Autoimmune Disease
(A) CD4+ T cells from Bl10 Rag2/ TCR transgenic specific for pigeon cytochrome c with or without deletion of the Il2 gene were polyclonally stim-
ulated for 3 days either in media alone (Th0); in the presence of IL-12 and anti IL-4 (Th1 conditions); in the presence of IL-23, anti-IFN-g, and anti-IL-4;
or in the presence of optimal Th17 differentiating conditions. The stimulations were performed in the presence or absence of IL-2 and subsequently
stained for IFN-g and IL-17. The numbers indicate the percentage of CD4+ T cells that express either IL-17 (top left quadrants) or IFN-g (bottom right
quadrants) and are representative of data from two independent experiments.
(B) CD4+ T cells from B10.ARag2/ 5C.C7 TCR transgenic mice with (top) or without (bottom) deletion of the Il2 gene were injected i.v. into congenic
(CD45.1) B10.A mice. The next day mice received s.c. injections of PCC peptide together with CFA. The draining lymph nodes were harvested after
7 days. Cells were stimulated for 4 hr with PMA and ionomycin, fixed and stained, and analyzed by flow cytometry. CD44, IL-17, and IFN-g expression
is shown for the gated CD45.2+ cell population. Representative data from four independent experiments are shown.repertoire. Thus, B10.A Il2/ Rag2/ 5C.C7 mice, which
express a transgenic T cell receptor (5C.C7) specific to the
nonendogenous antigen pigeon cytochrome c (PCC),
were used as a source of naive CD4+ T cells. Culture of
the Il2/ Rag2/ 5C.C7 T cells under optimal Th17 con-
ditions also resulted in a large proportion of IL-17-produc-
ing cells (Figure 3A, top). Again, the addition of exogenous
IL-2 to the cultures substantially reduced Th17 polariza-
tion. In contrast, IL-23, anti-IFN-g, and anti-IL-4 had no ef-
fect on polarization irrespective of IL-2, indicative of the
fact that this population did not include significant number
of memory CD4+ T cells (Veldhoen et al., 2006a). Finally,
the addition of IL-2 to Il2/Rag2/ CD4+ T cells stimu-
lated under Th1-polarizing conditions (IL-12 and anti-
IL-4) increased the proportion of cells expressing IFN-g.374 Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc.To further explore whether IL-2 has the capacity to reg-
ulate Th17 generation during a normal in vivo immune re-
sponse, in the presence of normal numbers of Treg cells,
no autoimmunity, and without the use of exogenous cyto-
kines, we used an adoptive transfer approach. Naive
B10.A Rag2/ 5C.C7 or B10.A Il2/ Rag2/ 5C.C7 T
cells (both CD45.2+) were injected intravenously into
B10.A congenic (CD45.1+) recipient mice and immunized
with cognate peptide. 7 days later, draining lymph nodes
were analyzed for T cell cytokine production. In this exper-
iment, 3.27% of B10.A Rag2/ 5C.C7 T cells became
IL-17 producers, consistent with recent reports (Murphy
et al., 2003). In contrast, more than twice as many Th17
cells were generated from B10.A Il2/Rag2/ 5C.C7 T
cells, whereas the numbers of IFN-g-producing cells were
Immunity
IL-2, Acting via STAT5, Inhibits Th17 Generationreduced. The data shown in Figure 3B are representative
of four experiments,which consistently showedadoubling
of IL-17 producers. Although the proportions of IL-17 pro-
ducers is small, it must be borne in mind that this experi-
ment represents in vivo Th17 differentiation in response
to vaccination, without addition of exogenous cytokines
or blocking antibodies. In contrast with the donor cells,
polyclonal nontransgenic host T cells were not activated
in this setting. CD44 expression was used to monitor
both the lack of responsiveness of the host cells (data
not shown) and the activation of the adoptively transferred
TCR transgenic T cells (Figure 3B, right). In both settings,
the recipient mice were not deficient in IL-2 and it is pos-
sible that this diminished the proportion of Th17 cells pres-
ent in the transgenic T cells. Nonetheless, in vivo, without
addition of exogenous cytokines, the presence of IL-2
clearly inhibited the proportion of IL-17-producing T cells.
Taken together, these data indicate that IL-2 regulates IL-
17 production in vitro and in vivo. Moreover, the overpro-
duction of IL-17 associated with IL-2 deficiency appears
not to be secondary to the autoimmune disease but is
a primary defect.
Opposing Roles of STAT3 and STAT5
in Th17 Differentiation
STAT3 is activated by IL-6 and IL-23, two cytokines that
promote IL-17 production by T cells (Harrington et al.,
2005; Veldhoen et al., 2006a). We therefore next analyzed
the importance of this transcription factor in IL-17 regula-
tion. In comparison to wild-type CD4+ T cells, T cells in
whichSTAT3 amountswere reduced througha conditional
Cre-lox targeted deletion revealed marked reduction in
the proportion of IL-17-producing cells, indicating a key
role in IL-17 regulation (Figure 4A). Conversely, the pro-
portion of FoxP3-expressing T cells was increased when
STAT3 was absent, indicative of its role in mediating IL-6
signaling to repress FoxP3 (Yao et al., 2007). The reduc-
tion in STAT3 was documented by immunoblotting (Fig-
ure 4B). The nuclear orphan receptor RORgt has recently
been identified as a critical transcription factor in the ex-
pression of IL-17A by CD4+ T cells (Ivanov et al., 2006).
We therefore compared RORgt mRNA expression in
Stat3-deleted CD4+ T cells compared with littermate con-
trols. In keeping with previous reports (Ivanov et al., 2006),
the expression of RORgt was elevated under Th17 condi-
tions in littermate controls but not in STAT3-deleted cells
(Figure 4C). Moreover, the addition of human IL-2 resulted
in a marked reduction in the expression of RORgt, sug-
gesting one mechanism of action by which IL-2 might
inhibit Th17 differentiation (Figure 4D).
IL-2-Mediated Activation of STAT5 Opposes Th17
Cell Differentiation
IL-2 and other common g chain (gc)-cytokines are potent
activators of STAT5a and STAT5b, transcription factors
that have critical in vivo functions in lymphoid develop-
ment (Beadling et al., 1994; Johnston et al., 1995; Yao
et al., 2006). Deletion of STAT5a and STAT5b via a trans-
genic expression of CD4-Cre (Stat5a/bfl/fl; CD4-Cre)with resultant expression in DP thymocytes results in loss
of CD8+ T cells in the periphery. The CD4+ T cells that
are present overwhelmingly exhibit a memory cell pheno-
type (Yao et al., 2006). We therefore in vitro polarized
Stat5a/bfl/fl; CD4-Cre and wild-type littermate splenic
CD4+ T cells as before in the presence of exogenous
IL-2 (Figure 5A). Wild-type T cells expressed similar num-
bers of Th17 cells as documented in previous experi-
ments, whereas, even when STAT5-deficient CD4+ T cells
were cultured under conditions that did not normally favor
IL-17 production (Th0), a large proportion of T cells selec-
tively produced IL-17 (Figure 5A, bottom left), suggesting
that these cells were prepolarized in vivo. In normal naive
CD4+ T cells, IL-23 does not induce differentiation into
IL-17 producers, but rather acts on memory T cells to ex-
pand this population (Mangan et al., 2006; Veldhoen et al.,
2006a). Accordingly, IL-23 exposure had minimal effects
on IL-17 production in wild-type T cells. However, IL-23
increased IL-17 production in Stat5a/bfl/fl; CD4-Cre
CD4+ T cells (Figure 5A, bottom middle), again consistent
with the existence of a prepolarized or memory population
of Th17 cells in Stat5a/bfl/fl; CD4-Cre mice.
To further explore the idea that Stat5a/bfl/fl; CD4-Cre
mice contain a pre-existing population of peripheral lym-
phocytes that can readily produce IL-17, we activated
Stat5a/bfl/fl; CD4-Cre CD4+ T cells with anti-CD3 and
anti-CD28 and analyzed their competency to produce
IL-17 by ELISA compared to littermate controls. We ob-
served dramatically increased amounts of IL-17 protein
in the Stat5a/bfl/fl; CD4-Cre cultures over those produced
by cultures of littermate controls at multiple time points
(Figure 5B). As further evidence of the tendency of
STAT5-deficient T cells to produce IL-17, significantly ele-
vated levels of this protein were detectable in the serum
of Stat5a/bfl/fl; CD4-Cre mice, compared to wild-type lit-
termates (p = 0.013) (Figure 5C). In interpreting this exper-
iment, it should be kept in mind that Stat5a/bfl/fl; CD4-Cre
mice are modestly lymphopenic compared to wild-type
and Il2/ mice; however, it is clear that absence of
STAT5 is associated with overproduction of IL-17 in vivo.
To circumvent the apparent prepolarization of periph-
eral STAT5-deficient T cells, we next used CD4+ single-
positive (SP) thymocytes from Stat5a/bfl/fl; CD4-Cre
mice and littermate controls. In contrast to peripheral
CD4+ lymphocytes from Stat5a/bfl/fl;CD4-Cremice, these
cells expressed naive cell markers (data not shown). CD4+
SP thymocytes were stimulated as before under Th0 con-
ditions or in the presence of neutralizing antibodies to-
gether with IL-23, TGF-b1, and IL-6 or TGF-b1 and IL-6
and IL-2 (Figure 6A). Few wild-type or Stat5a/bfl/fl; CD4-
Cre CD4+ SP thymocytes produced IL-17 in response to
IL-23, indicative of the absence of memory T cells. Both
cell populations produced IL-17 in response to TGF-b1
and IL-6; however, enhanced Th17 differentiation was
seen in Stat5a/bfl/fl; CD4-Cre CD4+ SP thymocytes.
Furthermore, the proportion of IL-17 producers was sig-
nificantly reduced by the addition of IL-2 (p = 0.012) in
wild-type cells, whereas this response was blocked in
Stat5a/bfl/fl; CD4-Cre CD4+ SP thymocytes (Figure 6B).Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 375
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IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 4. Critical Role of STAT3 in the Regulation of IL-17 and RORgt
(A) CD4+ T cells from Stat3fl/fl; MMTV-Cremice or littermate control mice were polyclonally stimulated for 3 days in media alone or under optimal Th17
conditions. The cells were subsequently analyzed for intracellular levels of FoxP3 and IL-17 by flow cytometry. The percentages indicated are
representative of data from three independent experiments.
(B) CD4+ T cells from Stat3fl/fl and Stat3fl/fl; MMTV-Cre mice polyclonally stimulated and expanded in IL-2-containing media were rested in media
without cytokine for 6 hr followed by a 5 min stimulation with IL-6 at 10 ng/mL. Cells were subsequently lysed and immunoblotted for the expression
of phospho-tyrosine STAT3, pan STAT3, and actin.
(C) CD4+ T cells from Stat3fl/flmice (white bars) orStat3fl/fl; MMTV-Cremice (black bars) were polyclonally stimulated for 3 days inmedia alone (Th0); in
the presence of IL-12 and anti IL-4 (Th1 conditions); in the presence of TGF-b1; or in the presence of optimal Th17 differentiating conditions. Cell
lysates were analyzed for the presence of RORgt mRNA by quantitative PCR, and values are normalized to the expression level in wild-type T cells
polarized under Th0 conditions. Histograms represent mean values and error bars represent SD values. The data shown are duplicates and are
representative of two independent experiments.
(D) CD4+ T cells from C57Bl6 mice were polyclonally stimulated for 3 days in media alone (Th0); in the presence of IL-12 and anti IL-4 (Th1 conditions);
in the presence of TGF-b1; or in the presence of optimal Th17 differentiating conditions all in the presence of anti-mouse IL-2 with (white bars) or
without (black bars) the addition of 100 iu/mL rhIL-2. Cell lysates were analyzed for the presence of RORgt mRNA by quantitative PCR, and values
are normalized to the expression level in wild-type T cells polarized under Th0 conditions. Histograms represent mean values and error bars represent
SD values. The data shown are duplicates and are representative of two independent experiments.Thus, STAT5a and STAT5b appear to be important in
limiting Th17 differentiation.
As indicated above, by using chromatin immunoprecip-
itation (ChIP), we have previously shown that STAT3 di-
rectly binds to the Il17a promoter and that STAT5 directly
binds the Foxp3 promoter (Chen et al., 2006; Yao et al.,
2007). We therefore considered the possibility that an-
other mechanism by which STAT5 might attenuate IL-17
production was by direct binding to the Il17a promoter.
Initial investigation of the Il17a promoter sequences high-376 Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc.lighted several potential STAT binding sites within2K bp
of the Il17a promoter. These sites were found within re-
gions denoted A–D indicated in Figure S2. The binding
of STAT5 to these regions was first assessed under condi-
tions that would be expected to maximize its binding (Bet-
telli et al., 2006; Yao et al., 2007). Specific STAT5 binding
was detected in all regions, although the region denoted D
had themost consistent IL-2-inducible binding (Figure S2).
Binding of STAT5 to the Foxp3 promoters was used as
a control (data not shown; Yao et al., 2007). We next
Immunity
IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 5. STAT5 Negatively Regulates Th17 Differentiation In Vitro and In Vivo
(A) CD4+ T cells from Stat5a/bfl/fl or Stat5a/bfl/fl; CD4-Cre mice were stimulated with anti-CD3 and anti-CD28 for 3 days in IL-2 alone or IL-2 together
with either IL-23, anti-IFN-g, and anti-IL-4; or under optimal Th17 conditions, and cells were subsequently stained for IFN-g and IL-17. Representative
data from two independent experiments are shown.
(B) CD4+ T cells from Stat5a/bfl/fl mice (white bars) or Stat5a/bfl/fl; CD4-Cre mice (black bars) were activated with anti-CD3 and anti-CD28, prior to
measuring levels of IL-17 protein in culture supernatants by ELISA at 24, 48, and 72 hr. Histograms represent mean values and error bars represent
SD values. The three asterisks denote a significant difference (p < 0.001) as determined by an unpaired t test. The values shown were measured in
triplicate and are representative of two independent experiments.
(C) Serum levels of IL-17 detected in wild-type (n = 5) and Stat5a/bfl/fl; CD4-Cre (n = 5) mice. The asterisk denotes a significant difference (p = 0.013)
as determined by an unpaired t test.used quantitative PCR to more carefully measure the in-
duction of STAT5 binding. Isolated CD4+ T cells were
stimulated with anti-CD3 and anti-CD28, washed to re-
move endogenously produced cytokines, and restimu-
lated with IL-2. In this setting, STAT5 specifically bound
to the Il17a gene (Figure 6C). Not surprisingly though,
CD4+ T cells activated with CD3 and CD28 alone (which
induces endogenous IL-2 production) also had very ap-
preciable amounts of binding of STAT5 to the Il17a gene.
DISCUSSION
In this study, we examined the role of IL-2 in Th17 gener-
ation and found that this cytokine appears to negatively
regulate IL-17 production in vivo and in vitro. Il2/ micehave widespread autoimmune disease, which has been
attributed to impaired Treg cell development and/or
function. Overproduction of IL-17 is a common feature
of many autoimmune and autoinflammatory disorders,
and dysregulation of IL-17 was a previously unappreci-
ated aspect of autoimmunity associated with IL-2 defi-
ciency. The inflammatory effects associated with overpro-
duction of this cytokine help to explain the severe,
systemic disease in Il2/ mice. It will be of interest in
the future to determine to what extent the pathology in
these mice is IL-17 dependent.
Because of the systemic abnormalities associated with
Il2/ deficiency, we considered the possibility that the
overproduction of IL-17 might be a secondary manifesta-
tion of disease and potentially not directly due to IL-2Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 377
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IL-2, Acting via STAT5, Inhibits Th17 GenerationFigure 6. Inhibition of Th17 Differentiation by IL-2 Requires STAT5
(A) CD4+ SP thymocytes from Stat5a/bfl/fl or Stat5a/bfl/fl; CD4-Cremice were stimulated with anti-CD3 and anti-CD28 for 3 days in media alone (Th0
conditions); together with IL-23, anti-IFN-g, and anti-IL-4; or under optimal Th17 conditions with and without the addition of 100 iu/ml IL-2. Cells were
fixed and stained for IL-17 and IFN-g expression. The data shown are representative of three independent experiments.
(B) Percentage of CD4+ T cells that expressed IL-17 was assessed by Student’s t test from three independent experiments with in vitro culture con-
ditions as described in (A). Histograms represent mean values fromStat5a/bfl/fl (white bars) orStat5a/bfl/fl; CD4-Cre (black bars) CD4+ SP thymocytes,
and error bars represent SD values. Significantly different levels p < 0.05 and p < 0.01 are denoted with a single or double asterisk, respectively.
(C) CD4+ T cells from C57Bl6 mice were polyclonally stimulated under neutral conditions for 3 days, rested in cytokine-free media (black bars), or
stimulated with IL-2 (white bars). Cell lysates were immunoprecipitated either with anti-STAT 5 or normal rabbit serum (NRS). Bound DNA was an-
alyzed by quantitative PCR with Il17a promoter site-specific primers to region D. Histograms represent mean values and error bars represent SD
values. The double asterisk denotes significant difference (p < 0.01) as determined by an unpaired t test. The values were measured in triplicate
and are representative of three independent experiments.itself. However, we also noted enhanced IL-17 production
in TCR transgenic, IL-2-deficient mice that did not have
autoimmune disease. Moreover, by using adoptive trans-
fer experiments, we observed increased propensity of
IL-2-deficient T cells to become IL-17 producers during
a normal vaccination response. Thus, even in the context
of normal numbers of Treg cells and without addition of
exogenous cytokines or cytokine antibodies, the capacity
of T cells to produce IL-2 regulated IL-17 production. This
is not to say that in the context of autoimmunity other
mechanisms might also contribute to IL-17 dysregulation;378 Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc.however, we believe that the present data argue that IL-2
is a relevant physiologic regulator of Th17 differentiation
independent of autoimmune disease. Our data suggest
a model in which IL-2, acting via STAT5, attenuates over-
production of IL-17, which in addition to its positive effects
on Treg cells provides another mechanism to constrain
immune-mediated damage to the host.
Recently, TGF-b1 has been implicated in the peripheral
induction of both Treg and Th17 cells (Bettelli et al., 2006;
Veldhoen et al., 2006a, 2006b). Whereas TGF-b1 is evi-
dently important for both lineages in vitro, this cytokine
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rather, the additional stimulus from proinflammatory
cytokines produced by dendritic cells including IL-6 and
IL-23 are needed. These cytokines activate STAT3 to di-
rect and maintain Th17 differentiation. In this regard, it is
notable that reduction in STAT3 levels resulted in impaired
Th17 differentiation. Previous studies from our laboratory
have documented direct binding of STAT3 to the Il17a
promoter, suggesting a direct role in transcriptional
regulation.
In contrast to IL-6 and IL-23, IL-2 provides a counterre-
gulatory mechanism that promotes Treg differentiation
and FoxP3 expression while concomitantly antagonizing
Th17 polarization. In this regard, it is worth noting that
Treg cells reportedly stimulate Th17 differentiation in vitro
via TGF-b1 production (Veldhoen et al., 2006a) but can
also inhibit IL-2 production (Thornton and Shevach,
1998), which could also promote Th17 polarization. IL-2
preferentially activates STAT5, and in contrast to STAT3,
STAT5 appears to negatively regulate IL-17 production.
Like Il2/ mice, Stat5/ mice have widespread autoim-
mune disease (Antov et al., 2003; Snow et al., 2003).
This has been attributed to impaired Treg cells, but
STAT5-deficient CD4+ T cells also exhibit dysregulation
of IL-17, which may be another contributor to the pathol-
ogy in these mice. While the overproduction of IL-17 sec-
ondarily might also be related to loss of Treg cells, autoim-
munity, or the memory phenotype of the CD4+ T cells, we
found that naive STAT5-deficient CD4+ SP thymocytes
also had increased propensity to become IL-17 pro-
ducers, and IL-2-dependent inhibition of Th17 generation
was blocked. Furthermore, STAT5 was found to bind the
Il17a promoter, suggesting that in contrast to STAT3, it
could serve as a repressor. This is of interest in that other
cytokines, which activate other STAT family transcription
factors, can also inhibit IL-17 production. Specifically,
IL-4 (which primarily activates STAT6) and IFN-g and
IL-27 (which activate STAT1) all inhibit IL-17 production
(Batten et al., 2006; Harrington et al., 2005; Stumhofer
et al., 2006). We have also observed binding of STAT1
and STAT6 to the Il17a promoter (data not shown). This
raises the intriguing possibility that different STAT family
members can recruit different coactivators or regulators
of chromatin modification. It will therefore be important
to determine precisely how different STAT family mem-
bers might positively and negatively IL17 transcription.
Alternatively, although STAT family transcription factors
have the potential to serve as direct repressors of Il17a,
they may also have indirect effects. For instance, STATs
regulate Socs3, which in turn also regulates Th17 cell dif-
ferentiation (Chen et al., 2006). Additionally, the actions of
STAT3 and 5 may occur via RORgt. Thus, STATs may
have both direct and indirect modes of regulating IL-17
production.
In summary, IL-2 and STAT5a/b, which were known to
be key regulators of Treg cells, also serve to constrain
Th17 polarization. It is notable that amajor cytokine, which
promotes clonal expansion, curtails the generation of
a highly inflammatory T cell subset. We envision the roleof IL-2 as another means of limiting inflammation that
might occur during immune responses. Homeostasis of
both lineages, Treg and Th17 cells, by IL-2 can ensure
that immune responses do not inflict damage to host tis-
sues. Understanding the precise mechanisms by which
cytokines and STAT family transcription factors regulate
these lineages will certainly be of continuing interest.
EXPERIMENTAL PROCEDURES
Mice
Mice bearing loxP-flanked conditional (fl/fl) alleles of STAT5 and
STAT3 on a C57BL/6J inbred background have been previously de-
scribed (Cui et al., 2004; Lee et al., 2002; Lee and Hennighausen,
2005; Yao et al., 2006). Stat3fl/fl mice were bred with mice expressing
Cre under the control of the MMTV-LTR (MMTV-Cre) to produce
Stat3fl/fl; MMTV-Cre mice. Stat3fl/fl mice were used as littermate con-
trols. Likewise, Stat5a/bfl/fl mice were bred with CD4-Cre transgenic
animals. Il2/ animals bred either on a C57Bl/6J or Bl10 Rag2/
TCR transgenic background were obtained from Taconic (Hudson,
NY) along with Bl10 Rag2/ TCR transgenic control mice. Animals
were handled and housed in accordance with the guidelines of the
NIH Animal Care and Use Committee.
Isolation of Cells and Cell Culture
Splenocytes were obtained by disrupting organs of 8- to 10-week-old
mice. Unless stated otherwise, all cell cultureswere performed in RPMI
supplemented with 10% fetal calf serum, 2 mM glutamine, 100 iu/mL
penicillin, 0.1 mg/mL streptomycin (Biosource International, USA),
and 2 mM b-mercaptoethanol. T cells were enriched with a Mouse
CD4+ T Cell Isolation Kit with an autoMacs (Miltenyi Biotec, Bergisch
Gladbach, Germany). Naive T cells were obtained by surface staining
with anti-CD62L, anti-CD44, and anti-CD25. The CD62L+ CD44
CD25 population was isolated by flow cytometry cell sorting with
a Mo-Flo cell sorter (Dako Carpinteria, CA). Cells were activated by
plate-bound anti-CD3 (5 mg/mL) and soluble anti-CD28 (5 mg/mL)
(BD PharMingen, San Diego, CA) for 3 days (unless otherwise indi-
cated) and cultured either under neutral conditions (Th0): with IL-23
(10 ng/ml, R&D Systems, Minneapolis, MN), anti-IFN-g, and anti-IL-4
(both at 10 mg/mL, BD PharMingen, San Diego, CA); under Th1 condi-
tions (IL-12 at 10 ng/ml, R&D Systems with anti-IL-4); or under optimal
Th17 culture conditions: IL-6 (10 ng/ml, R&D Systems), TGF-b1
(5 ng/ml, R&D Systems), anti-IFN-g, and anti-IL4. Where indicated, hu-
man IL-2 (100 iu/mL) or anti-murine IL-2 (10 mg/ml, kindly provided by
C.A. Hunter, University of Pennsylvania) was added to the cell culture.
Adoptive Transfer Experiments
Naive CD4+ T cells used for adoptive transfer were obtained from the
peripheral lymph organs of B10.A Rag2/ 5C.C7 or B10.A Il2/
Rag2/ 5C.C7 TCR transgenic mice. 106 cells were injected i.v. into
CD45.1+ B10.A mice. The next day, each recipient received 40 mg
PCC peptide together with 4 mg/mL complete Freunds adjuvant
(a total of 400 mg heat-killed tuberculosis) s.c. After 7 days, the mice
were killed and the draining lymph nodes were harvested. Peripheral
lymphocytes were stimulated for 4 hr with phorbol myristate acetate,
and ionomycin with Golgistop added after 2 hr. Stimulated cells
were analyzed for IFN-g and IL-17 expression by flow cytometry as
described below.
Measurement of Cytokines
Detection of IFN-g-, IL-17-producing cells and FoxP3-expressing cells
was determined by intracellular cytokine staining with anti-IFN-g-APC,
anti-IL-17-PE (BD Biosciences), or anti-FoxP3-FITC (eBiosciences). In
brief, cells were stimulated for 4 hr with phorbol myristate acetate and
ionomycin with Golgistop added after 2 hr. Cell stimulation was termi-
nated by fixing in 4% formyl saline. Fixed cells were stained with fluo-
rescent antibodies in 0.1% saponin permeablization buffer andImmunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 379
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were collected and analyzed with Flow Jo software (Tree Star Inc,
Ashland, OR). Cytokine production in cell culture supernatants was
analyzed by enzyme-linked immunosorbent assay (ELISA) with mouse
IL-17 Quantikine assay kits (R&D Systems) according to the manufac-
turer’s instructions.
Determination of STAT3 Deletion
STAT3 protein concentration in T lymphoblasts after treatment with
IL-6 was determined by western blotting of whole-cell lysates with
anti-phospho-STAT3 and anti (pan) STAT3 polyclonal antibodies
(Cell Signal Technology). Total protein was determined by reprobing
membranes with actin monoclonal antibody (Chemicon International).
Preparation of cell lysates and immunoblotting were as described
previously (Astoul et al., 2003).
Determination of RORgt mRNA Expression
cDNA was made from lysates of two million cells with the RNeasy kit
(Qiagen, MD). Quantitative PCR was performed with an ABI PRISM
7700 sequence detection system with site-specific primers and
probes (Applied Biosystems, Foster City, CA).
Chromatin Immunopreciptation
ChIP was performed as previously described (Chen et al., 2006). To
summarize, unless indicated otherwise, CD4+ Th cells were polyclo-
nally activated for 3 days followed by resting in cytokine-free media
for 24 hr followed by the addition of IL-2 (100 iu/mL) for 1 hr. DNA-
bound transcription factors were subsequently crosslinked by infusing
complete medium containing 1% formaldehyde for 10 min followed by
sonication of the cell lysate. After preclearing with protein A agarose
beads (Upstate, Charlottesville, VA), cell lysates from five million cells
were immunoprecipitated with anti-STAT5 antibody (R&D Systems) or
normal rabbit serum (Upstate USA, Chicago, IL) overnight at 4C. After
washing and elution, crosslinks were reversed at 65C for 4 hr. The
eluted DNA was purified and samples analyzed by either conventional
PCR or quantitative-PCR with Il17a promoter site-specific primers.
Primers used are as follows. Region A, forward GCC TTT GTG ATT
GTT TCT TGC, reverse TGT GAG TCT CTT GAC AGT CTC; Region
B, forward ACC TCA TGC TGC ATG TCA GAC, reverse CTG AAA
GAC AGT GGA GAC ACT; Region C, forward CAA TCA GAG GTG
TGT GTG AGC, reverse GTC TGA CAT GCA GCA GCA TGA GGT;
Region D, forward GCT CAG CAG TTA AGA GTA CTG, reverse ACA
TAC CAC AAC ATT GGC TTC. In the case of quantitative PCR, ABI
PRISM 7700 sequence detection system (Applied Biosystems) was
used with the following primers and probe: forward primer, GGA
GAG ATG GCT CAG CAG TTA AG; reverse primer, TGG TTT CTG
GGA ATT GAA CTC A; probe, TAC TGA CTG CTC TTC CAG AGG.
The Ct value for each sample was normalized to corresponding input
value and expressed as fold induction relative to the normal rabbit
serum control, which was arbitrary set as 1.0.
Supplemental Data
Two Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/26/3/371/DC1/.
ACKNOWLEDGMENTS
We thank R. Casellas and W. Paul for reading the manuscript and pro-
viding helpful suggestions. There are no conflicts of interest.
Received: October 29, 2006
Revised: January 23, 2007
Accepted: February 15, 2007
Published online: March 15, 2007380 Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc.REFERENCES
Abbas, A.K. (2003). The control of T cell activation vs. tolerance. Auto-
immun. Rev. 2, 115–118.
Abbas, A.K., Murphy, K.M., and Sher, A. (1996). Functional diversity of
helper T lymphocytes. Nature 383, 787–793.
Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J., and Gurney,
A.L. (2003). Interleukin-23 promotes a distinct CD4 T cell activation
state characterized by the production of interleukin-17. J. Biol.
Chem. 278, 1910–1914.
Antov, A., Yang, L., Vig, M., Baltimore, D., and Van Parijs, L. (2003).
Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell ho-
meostasis and the maintenance of self-tolerance. J. Immunol. 171,
3435–3441.
Astoul, E., Laurence, A.D., Totty, N., Beer, S., Alexander, D.R., and
Cantrell, D.A. (2003). Approaches to define antigen receptor-induced
serine kinase signal transduction pathways. J. Biol. Chem. 278,
9267–9275.
Batten, M., Li, J., Yi, S., Kljavin, N.M., Danilenko, D.M., Lucas, S., Lee,
J., de Sauvage, F.J., and Ghilardi, N. (2006). Interleukin 27 limits auto-
immune encephalomyelitis by suppressing the development of inter-
leukin 17-producing T cells. Nat. Immunol. 7, 929–936.
Beadling, C., Guschin, D.,Witthuhn, B.A., Ziemiecki, A., Ihle, J.N., Kerr,
I.M., and Cantrell, D.A. (1994). Activation of JAK kinases and STAT
proteins by interleukin-2 and interferon alpha, but not the T cell antigen
receptor, in human T lymphocytes. EMBO J. 13, 5605–5615.
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T.B., Oukka, M., Wei-
ner, H.L., and Kuchroo, V.K. (2006). Reciprocal developmental path-
ways for the generation of pathogenic effector TH17 and regulatory
T cells. Nature 441, 235–238.
Chen, Z., Laurence, A., Kanno, Y., Pacher-Zavisin, M., Zhu, B.M., Tato,
C., Yoshimura, A., Hennighausen, L., and O’Shea, J.J. (2006). Selec-
tive regulatory function of Socs3 in the formation of IL-17-secreting T
cells. Proc. Natl. Acad. Sci. USA 103, 8137–8142.
Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour,
B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003). Interleu-
kin-23 rather than interleukin-12 is the critical cytokine for autoimmune
inflammation of the brain. Nature 421, 744–748.
Cui, Y., Riedlinger, G., Miyoshi, K., Tang, W., Li, C., Deng, C.X., Rob-
inson, G.W., and Hennighausen, L. (2004). Inactivation of STAT5 in
mouse mammary epithelium during pregnancy reveals distinct func-
tions in cell proliferation, survival, and differentiation. Mol. Cell. Biol.
24, 8037–8047.
Flavell, R.A. (1999). The molecular basis of T cell differentiation. Immu-
nol. Res. 19, 159–168.
Glimcher, L.H. (2001). Lineage commitment in lymphocytes: control-
ling the immune response. J. Clin. Invest. 108, s25–s30.
Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L.,
Murphy, K.M., and Weaver, C.T. (2005). Interleukin 17-producing
CD4+ effector T cells develop via a lineage distinct from the T helper
type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132.
Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A.,
Lafaille, J.J., Cua, D.J., and Littman, D.R. (2006). The orphan nuclear
receptor RORgammat directs the differentiation program of proinflam-
matory IL-17(+) T helper cells. Cell 126, 1121–1133.
Johnston, J.A., Wang, L.M., Hanson, E.P., Sun, X.J., White, M.F.,
Oakes, S.A., Pierce, J.H., and O’Shea, J.J. (1995). Interleukins 2, 4,
7, and 15 stimulate tyrosine phosphorylation of insulin receptor sub-
strates 1 and 2 in T cells. Potential role of JAK kinases. J. Biol.
Chem. 270, 28527–28530.
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham,
B., Sedgwick, J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J.
(2005). IL-23 drives a pathogenic T cell population that induces auto-
immune inflammation. J. Exp. Med. 201, 233–240.
Immunity
IL-2, Acting via STAT5, Inhibits Th17 GenerationLee, J.Y., and Hennighausen, L. (2005). The transcription factor STAT3
is dispensable for pancreatic beta-cell development and function.
Biochem. Biophys. Res. Commun. 334, 764–768.
Lee, C.K., Raz, R., Gimeno, R., Gertner, R., Wistinghausen, B., Take-
shita, K., DePinho, R.A., and Levy, D.E. (2002). STAT3 is a negative
regulator of granulopoiesis but is not required for G-CSF-dependent
differentiation. Immunity 17, 63–72.
Li, M.O., Sanjabi, S., and Flavell, R.A. (2006). Transforming growth
factor-beta controls development, homeostasis, and tolerance of T
cells by regulatory T cell-dependent and -independent mechanisms.
Immunity 25, 455–471.
Malek, T.R. (2003). The main function of IL-2 is to promote the devel-
opment of T regulatory cells. J. Leukoc. Biol. 74, 961–965.
Mangan, P.R., Harrington, L.E., O’Quinn, D.B., Helms, W.S., Bullard,
D.C., Elson, C.O., Hatton, R.D., Wahl, S.M., Schoeb, T.R., andWeaver,
C.T. (2006). Transforming growth factor-beta induces development of
the T(H)17 lineage. Nature 441, 231–234.
Marie, J.C., Liggitt, D., and Rudensky, A.Y. (2006). Cellular mecha-
nisms of fatal early-onset autoimmunity in mice with the T cell-specific
targeting of transforming growth factor-beta receptor. Immunity 25,
441–454.
McKarns, S.C., Schwartz, R.H., and Kaminski, N.E. (2004). Smad3 is
essential for TGF-beta 1 to suppress IL-2 production and TCR-in-
duced proliferation, but not IL-2-induced proliferation. J. Immunol.
172, 4275–4284.
McKenzie, B.S., Kastelein, R.A., and Cua, D.J. (2006). Understanding
the IL-23-IL-17 immune pathway. Trends Immunol. 27, 17–23.
Mosmann, T.R., and Coffman, R.L. (1989). TH1 and TH2 cells: different
patterns of lymphokine secretion lead to different functional proper-
ties. Annu. Rev. Immunol. 7, 145–173.
Murphy, K.M., and Reiner, S.L. (2002). The lineage decisions of helper
T cells. Nat. Rev. Immunol. 2, 933–944.
Murphy, C.A., Langrish, C.L., Chen, Y., Blumenschein, W., McClana-
han, T., Kastelein, R.A., Sedgwick, J.D., and Cua, D.J. (2003). Diver-
gent pro- and antiinflammatory roles for IL-23 and IL-12 in joint
autoimmune inflammation. J. Exp. Med. 198, 1951–1957.
Refaeli, Y., and Abbas, A.K. (1998). Role of cytokines in autoimmunity.
Eur. Cytokine Netw. 9, 81–82.
Refaeli, Y., Van Parijs, L., and Abbas, A.K. (1999). Genetic models of
abnormal apoptosis in lymphocytes. Immunol. Rev. 169, 273–282.
Shevach, E.M., DiPaolo, R.A., Andersson, J., Zhao, D.M., Stephens,
G.L., and Thornton, A.M. (2006). The lifestyle of naturally occurring
CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212, 60–73.Snow, J.W., Abraham, N., Ma, M.C., Herndier, B.G., Pastuszak, A.W.,
and Goldsmith, M.A. (2003). Loss of tolerance and autoimmunity
affecting multiple organs in STAT5A/5B-deficient mice. J. Immunol.
171, 5042–5050.
Strober, W., Ludviksson, B.R., and Fuss, I.J. (1998). The pathogenesis
of mucosal inflammation in murine models of inflammatory bowel dis-
ease and Crohn disease. Ann. Intern. Med. 128, 848–856.
Stumhofer, J.S., Laurence, A., Wilson, E.H., Huang, E., Tato, C.M.,
Johnson, L.M., Villarino, A.V., Huang, Q., Yoshimura, A., Sehy, D.,
et al. (2006). Interleukin 27 negatively regulates the development of in-
terleukin 17-producing T helper cells during chronic inflammation of
the central nervous system. Nat. Immunol. 7, 937–945.
Suzuki, H., Kundig, T.M., Furlonger, C., Wakeham, A., Timms, E., Mat-
suyama, T., Schmits, R., Simard, J.J., Ohashi, P.S., Griesser, H., et al.
(1995). Deregulated T cell activation and autoimmunity in mice lacking
interleukin-2 receptor beta. Science 268, 1472–1476.
Thornton, A.M., and Shevach, E.M. (1998). CD4+CD25+ immunoregu-
latory T cells suppress polyclonal T cell activation in vitro by inhibiting
interleukin 2 production. J. Exp. Med. 188, 287–296.
Umetsu, D.T., McIntire, J.J., Akbari, O., Macaubas, C., and DeKruyff,
R.H. (2002). Asthma: an epidemic of dysregulated immunity. Nat.
Immunol. 3, 715–720.
Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M., and Stock-
inger, B. (2006a). TGFbeta in the context of an inflammatory cytokine
milieu supports de novo differentiation of IL-17-producing T cells.
Immunity 24, 179–189.
Veldhoen, M., Hocking, R.J., Flavell, R.A., and Stockinger, B. (2006b).
Signals mediated by transforming growth factor-beta initiate autoim-
mune encephalomyelitis, but chronic inflammation is needed to sus-
tain disease. Nat. Immunol. 7, 1151–1156.
Yao, Z., Cui, Y., Watford, W.T., Bream, J.H., Yamaoka, K., Hissong,
B.D., Li, D., Durum, S.K., Jiang, Q., Bhandoola, A., et al. (2006).
STAT5a/b are essential for normal lymphoid development and differ-
entiation. Proc. Natl. Acad. Sci. USA 103, 1000–1005.
Yao, Z., Kanno, Y., Kerenyi, M., Stephens, G., Durant, L., Watford,
W.T., Laurence, A., Robinson, G.W., Shevach, E.M., Morrigl, R.,
et al. (2007). Nonredundant roles for STAT5a/b in directly regulating
Foxp3. Blood Press. Published online January 16, 2007. 10.1182/
blood-2006-11-055756.
Ye, P., Rodriguez, F.H., Kanaly, S., Stocking, K.L., Schurr, J., Schwar-
zenberger, P., Oliver, P., Huang, W., Zhang, P., Zhang, J., et al. (2001).
Requirement of interleukin 17 receptor signaling for lung CXC chemo-
kine and granulocyte colony-stimulating factor expression, neutrophil
recruitment, and host defense. J. Exp. Med. 194, 519–527.Immunity 26, 371–381, March 2007 ª2007 Elsevier Inc. 381
